Please login to the form below

Not currently logged in
Email:
Password:

nintedanib

This page shows the latest nintedanib news and features for those working in and with pharma, biotech and healthcare.

FDA priority review for Roche’s Esbriet in unclassifiable interstitial lung disease

FDA priority review for Roche’s Esbriet in unclassifiable interstitial lung disease

Another major IPF drug and Esbriet’s main rival – Boehringer Ingelheim’s Ofev (nintedanib) – picked up an FDA approval for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Latest news

More from news
Approximately 9 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    The drug is predicted to take a 50% share of the estimated $2bn IPF market, the main competitor being Boehringer Ingelheim's nintedanib currently in late stage development.  .

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    It's a method that is also seeing Boehringer enter the increasingly attractive rare diseases market through its investigational drug nintedanib, which is in studies assessing its effectiveness as a treatment ... This is in addition to nintedanib's

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....